Inhibrx IPO

9/19/2020

IPO

$119,000,000

Per the firm's most recent regulatory filing, it plans to use the net proceeds as follows:approximately $30.0 million to fund the remainder of dose expansion in our ongoing Phase 1 clinical trial for our INBRX-109 program to initial data, initiate combination studies as well as to fund commercial manufacturing scale-up activities;approximately $10.0 million to fund the remainder of dose escalation in our ongoing Phase 1 clinical trial for our INBRX-106 program to initial data, for both single agent and in combination with Keytruda;approximately $10.0 million to fund the remainder of dose escalation in our ongoing Phase 1 clinical trial for our INBRX-105 program to initial data and to fund commercial manufacturing scale-up activities;approximately $25.0 million to fund the remainder of our ongoing Phase 1 clinical trial for our INBRX-101 program to initial data and to fund commercial manufacturing scale-up activities; andthe remainder for our other research and development activities, a

Publicly-held

Biopharmaceutical

11025 North Torrey Pines Rd. 200
La Jolla, CA 92037
USA

Undisclosed

Not Recorded

At Inhibrx (Nasdaq: INBX), our mission is to deliver optimized, biologic therapeutics to people with life-threatening conditions. Toward this goal, we have built a large and diverse pipeline with the potential to impact cancer, infectious disease and orphan diseases.